[{"id":"b4375855-bbf2-4799-83aa-03c121a7f1f7","acronym":"ToPCourT","url":"https://clinicaltrials.gov/study/NCT06027268","created_at":"2023-09-07T16:09:45.091Z","updated_at":"2025-02-25T16:19:05.553Z","phase":"Phase 2","brief_title":"Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT06027268 - ToPCourT","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-04"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"7d9b53ef-b645-44ee-9c8e-8c8c3875b0f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06569485","created_at":"2025-02-26T12:22:38.642Z","updated_at":"2025-02-26T12:22:38.642Z","phase":"Phase 2","brief_title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients","source_id_and_acronym":"NCT06569485","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20","pipe":"","alterations":" ","tags":["CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/23/2024","start_date":" 05/23/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-08-26"},{"id":"75733836-727c-4fc3-a5df-43cedb61f88f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05112536","created_at":"2021-11-09T20:21:17.276Z","updated_at":"2024-07-02T16:35:15.209Z","phase":"Phase 2","brief_title":"Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT05112536","lead_sponsor":"G1 Therapeutics, Inc.","biomarkers":" ER • PGR • CD8","pipe":"","alterations":" ","tags":["ER • PGR • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Cosela (trilaciclib) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/03/2022","start_date":" 03/03/2022","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 03/13/2023","study_completion_date":" 03/13/2023","last_update_posted":"2024-03-12"},{"id":"dea11325-de73-4f61-998d-8e7f27135543","acronym":"PRESERVE 2","url":"https://clinicaltrials.gov/study/NCT04799249","created_at":"2021-03-16T18:52:52.934Z","updated_at":"2024-07-02T16:35:23.360Z","phase":"Phase 3","brief_title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT04799249 - PRESERVE 2","lead_sponsor":"G1 Therapeutics, Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Cosela (trilaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 10/25/2024","study_completion_date":" 10/25/2024","last_update_posted":"2024-01-15"},{"id":"9d2cfc9b-82d5-496a-9443-80543cf607c5","acronym":"SMA-BC-002","url":"https://clinicaltrials.gov/study/NCT05978648","created_at":"2023-08-07T14:08:51.211Z","updated_at":"2025-02-25T12:29:41.505Z","phase":"Phase 2","brief_title":"Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy","source_id_and_acronym":"NCT05978648 - SMA-BC-002","lead_sponsor":"wang shusen","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • HER-2 negative + HR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 09/20/2023","start_date":" 09/20/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-11-30"},{"id":"6652628c-ad51-4797-8f15-72f4094ba21f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05578326","created_at":"2022-10-13T17:58:14.557Z","updated_at":"2024-07-02T16:35:29.032Z","phase":"Phase 2","brief_title":"Study of Trilaciclib and Lurbinectidin","source_id_and_acronym":"NCT05578326","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin) • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 07/25/2024","primary_completion_date":" 07/25/2024","study_txt":" Completion: 07/25/2026","study_completion_date":" 07/25/2026","last_update_posted":"2023-11-16"},{"id":"00d13a79-2626-44a2-a0e6-b30680c3033d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05862610","created_at":"2023-05-17T14:05:24.846Z","updated_at":"2024-07-02T16:35:42.146Z","phase":"Phase 2","brief_title":"The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC","source_id_and_acronym":"NCT05862610","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • epirubicin • Cosela (trilaciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 07/30/2023","start_date":" 07/30/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2023-07-24"}]